The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessAbstract
BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Overview
CoChat Summary
## TL;DR
The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.
## Key findings
- The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
- At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
- In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
- Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).
## Methods
- Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
- The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
- Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.
## Limitations
- The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
- The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
- Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Standard risk | 182/266 (68.4) | 234/264 (88.6) | | 3.60 (2.27–5.70) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Non-IgG | 73/96 (76.0) | 72/78 (92.3) | | 3.78 (1.45–9.83) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| ≥65 years | 62/87 (71.3) | 77/94 (81.9) | | 1.83 (0.91–3.68) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Male | 94/205 (45.9) | 150/211 (71.1) | | 2.90 (1.94–4.35) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| <65 years | 186/267 (69.7) | 235/261 (90.0) | | 3.94 (2.43–6.37) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 11
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The quadruplet regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) has recently emerged as standard of care option for initial therapy in transplant eligible patients with newly diagnosed myeloma.101,111”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The role of daratumumab in patients who received it as part of frontline therapy is unclear.101,152”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204925 · Cited by 487
Self-citation
Cited by
Items 101–200 of 588
Moore, D. C., Elsey, G., McElwee, J., & Atrash, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2595122 · Cited by 7
Toward a cure for multiple myeloma within a decade
Mohty, M., Malard, F., Facon, T. T. F., & Harousseau, J. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01461-7 · Cited by 8
“In both standard-and high-risk cytogenetic subgroups, PFS at 48 months in patients achieving sustained MRD negativity exceeded 94% [13].”
Minimal residual disease in multiple myeloma
Moukalled, N. M., Malard, F., Bazarbachi, A. A., & Mohty, M. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104261 · Cited by 7
Liang, D., Yan, Y., Bai, S., Xu, W., Wang, Q.-L., Feng, D., Zeng, M., Nie, X., Feng, Y., Chen, X., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13309-z · Cited by 8
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Hadidi, S. A., Ababneh, O. E., Schinke, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014889 · Cited by 6
Costa, L. J., Medvedova, E., Dhakal, B., Dholaria, B., Godby, K. N., Bal, S., Ravi, G., Giri, S., Chhabra, S., Silbermann, R. W., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01219-7 · Cited by 6
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Lal, B. M., van Rhee, F., & Hadidi, S. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01639-5 · Cited by 8
“In patients with HRMM, the MRD negativity rates at any time with this quadruplet regimen ranged from 68 to 79%, and after consolidation ranged from 60–77% [69, 70, 73, 75].”
InfluentialKikuchi, T., Watanabe, M., Tsukada, N., Matsumoto, C., Nomura‐Yogo, M., Kunisada, K., Sawada, H., Sato, K., Takei, T., Ogura, M., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70040 · Cited by 6
Ntanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Koutoulidis, V., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Cancers · doi:10.3390/cancers17121943 · Cited by 7
“…of anti-CD38 monoclonal antibodies has now increased interest in quadruplet first-line regimens, as key randomized clinical trials have demonstrated deeper responses, including higher rates of minimal residual disease (MRD) negativity, as well as prolonged PFS in patients with NDMM [15–17].”
Self-citationMehl, J., Akhoundova, D., Bacher, U., Jeker, B., Agocs, G. R., Ruefer, A., Soltermann, S., Soekler, M., Winkler, A., Daskalakis, M., et al. (2024) · Cancers · doi:10.3390/cancers16101854 · Cited by 9
“However, the addition of daratumumab to newly diagnosed MM (NDMM) induction therapy is being increasingly implemented in clinical practice since recent studies have shown that daratumumab-containing regimens improve depth and duration of response compared to induction without daratumumab [6–9].”
MethodResultLiang, D., Li, X., Bai, S., Wang, Q.-L., Zeng, M., Feng, D., Lü, B., Li, X., Sun, Z., Li, J., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70270 · Cited by 7
China's potential role in humanitarian assistance
Binder, A., & Conrad, B. (2009) · Cited by 9
Tao, J., Wang, L., Gu, Z., et al. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0701 · Cited by 5
Kuroki, W., Kitadate, A., Takahashi, Y., Iwama, S., Yamada, M., Kobayashi, T., Ikeda, S., Narita, K., Matsue, K., & Takahashi, N. (2025) · British Journal of Haematology · doi:10.1111/bjh.20106 · Cited by 12
Martino, E. A., Caridà, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105514 · Cited by 7
The role of stem cell transplantation in the modern management of multiple myeloma
Villar, S., Zapata, E., & Rifón, J. (2025) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000896 · Cited by 4
The past, present, and future of myeloma staging and risk prognostication
Baysal, M., Julian, K. L., Sborov, D. W., Godara, A., McClune, B. L., Lohr, J. G., Fortuna, G. G., & Mohyuddin, G. R. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf299 · Cited by 7
Lin, P. Y., Acharya, S., Reyes-Silva, F., Başar, R., Uprety, N., Rueda, L. Y. M., Lin, P., Gilbert, A. L., Banerjee, P. P., Fang, D., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0130 · Cited by 10
“…with high-risk cytogenetics continue to experience earlier relapses and achieve less durable responses compared with those with standard-risk disease, even with intensive approaches such as autologous stem cell transplantation (20), maintenance treatment (21), or quadruplet induction regimens (22).”
Sarkar, S., & Suresh, P. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1701031 · Cited by 6
Beksac, M., Tuğlular, T., Gay, F., Mina, R., Katodritou, E., Ünal, A., Cavo, M., Özsan, G. H., van der Velden, V. H. J., Beverloo, B. H. B., et al. (2026) · HemaSphere · doi:10.1002/hem3.70287 · Cited by 5
“27 Without doubt, DaraVCD induction yielded CR rates inferior FIGURE 1 Progression ‐ free survival by type of multiple myeloma (A), type of hematological and metabolic response (B), type of metabolic response and minimal residual disease (MRD) negativity (C), number of plasmacytomas (D), type of…”
Self-citationDiagnosis, risk stratification and management of smouldering multiple myeloma
Zanwar, S., Kumar, S. K., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01119-0 · Cited by 8
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Kumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N. S., Singh, A., Parker, T. L., Green, M., Thertulien, R., Parsons, B. M., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600157 · Cited by 7
Lim, S., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I., Janowski, W., Bergin, K., & Spencer, A. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19578 · Cited by 6
“Inherent bortezomib resistance exhibited as either SOR or primary refractoriness remains a significant clinical challenge in the management of NDMM.”
InfluentialSelf-citationMultiple myeloma and infections in the era of novel treatment modalities
Akhmedov, M., Zeynalova, P. A., & Феденко, А. А. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107544 · Cited by 8
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Shim, K. G., & Fonseca, R. (2024) · Cancers · doi:10.3390/cancers16193288 · Cited by 6
“Similarly, the large, randomized phase III clinical trial, PERSEUS, has incorporated attainment of MRD negativity in patients with a complete response as a criterion to stop maintenance therapy [31].”
BackgroundKhan, S., Bergstrom, D. J., Côté, J. A., Kotb, R. R., LeBlanc, R., Louzada, M., Mian, H. S., Othman, I., Colasurdo, G., & Visram, A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.012 · Cited by 6
The characteristics of patients with multiple myeloma surviving over 10 years
Huang, B., Zhang, H., Liu, J., Gu, J., Chen, M.-L., Kuang, L., Li, X., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1490630 · Cited by 5
Wang, H., Liang, L., Xie, Y., Gong, H., Fan, F., Wen, C., Yu, J., Lei, S., Qiu, X., Peng, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03245-4 · Cited by 6
“Although current multi-drug combination therapies have signi fi cantly improved patient outcomes [4, 5], they remain inadequate in preventing drug resistance and disease relapse, rendering MM incurable [6, 7].”
New Immunosuppressants in Pediatric Kidney Transplantation: What's in the Pipeline for Kids?
Tönshoff, B., Patry, C., Fichtner, A., Höcker, B., & Böhmig, G. A. (2024) · Pediatric Transplantation · doi:10.1111/petr.70008 · Cited by 8
“Depletion of malignant plasma cells with CD38 monoclonal antibodies has been approved for the treatment of multiple myeloma [86–88].”
Iida, S., Yasutomi, Y., Samyshkin, Y., Chen, Y.-C., Chen, C., Lee, W. S., Kim, S.-W., McGuiness, C. B., Zhou, Z., & McNamara, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315932 · Cited by 6
Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?
Mian, H. S., & Costa, L. J. (2025) · American Journal of Hematology · doi:10.1002/ajh.70002 · Cited by 5
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Richardson, P. G. G., O’Donnell, E. K., O’Gorman, P., Leypoldt, L. B., Laubach, J. P., Gay, F., Leleu, X. P., Facon, T. T. F., Moreau, P., Dimopoulos, M. A., et al. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2532446 · Cited by 5
“Historical SOCs for Te NDMM have included induction/consolidation therapy with the triplet combination of RVd [41,42,55] and, more recently [4], the addition of a CD38-targeting mAb to VRd [13,56,57].”
Self-citationMcCaughan, G. J. B., Beer, H., Bryant, C. E., Ho, P. J., King, T., Lee, C., Mollee, P. N., Prince, H. M., Spencer, A. G., Talaulikar, D., et al. (2025) · Internal Medicine Journal · doi:10.1111/imj.70148 · Cited by 4
Self-citationSilbermann, R. W., Laubach, J. P., Kaufman, J. L., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Costa, L. J., Anderson, L. D., Nathwani, N., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27326 · Cited by 6
Voorhees, P. M., Suman, V. J., Efebera, Y. A., Raje, N. S., Tuchman, S. A., Valdes, C. R., Laubach, J. P., Bova‐Solem, M., Carlisle, D., Usmani, S. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013623 · Cited by 9
Precision medicine for multiple myeloma: The case for translocation (11;14)
Bazarbachi, A. H., Avet‐Loiseau, H., Harousseau, J., Bazarbachi, A., & Mohty, M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102823 · Cited by 5
Lytvynova, O., Jwayyed, J., Pastel, D., Prasad, R., Khouri, J., Williams, L., Mazzoni, S. A., Raza, S., & Anwer, F. (2024) · Antibodies · doi:10.3390/antib13040080 · Cited by 6
“Serious TEAEs leading to treatment discontinuations were noted to be higher in the Dara-VRd group versus the VRd group (57% vs. 49.9%, respectively) [15,16].”
BackgroundMethodInfluentialBertuglia, G., Garibaldi, B., Casson, A., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02432-x · Cited by 5
Self-citationSurvival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France
Perrot, A., RAGUIDEAU, F., Denis, H., Prodel, M., Javelot, M., Pierrès, M., & Touzeau, C. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.004 · Cited by 6
Self-citationLahuerta, J. J., San-Miguel, J., Ubieto, A. J., Alonso, R., Paiva, B., Puig, N., Cedena, M., Gutierrez, N. C., Calasanz, M. J., Guijarro, M. F., et al. (2025) · Blood · doi:10.1182/blood.2025028313 · Cited by 6
Self-citationTreatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study
Yoon, J., Jung, J., Park, B., Lee, E., Park, Y. S., Yoon, S., & Eom, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13615-0 · Cited by 4
“For transplant-eligible patients, the combination of daratu-mumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) with lenalidomide for maintenance showed a significant benefit compared to VRd regimen, which is currently the most widely used regimen in Korea [25].”
Chen, W., Cai, Z., Chim, J. C., Chng, W. J., Du, J., Fu, C., Hanamura, I., Hou, J. M., Huang, J., Ishida, T., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.133682 · Cited by 8
Molecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
“35-38 Collectively, maintenance therapies sustain deep responses and reinforce immune-mediated disease control.”
Askari, E., Dispenzieri, A. A., Buadi, F. K., Hayman, S. R., Gertz, M. A., Kapoor, P., Gonsalves, W. I., Kourelis, T., Dingli, D., Warsame, R. M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01340-7 · Cited by 7
Zheng, S., He, J., Song, X., Ye, P., Yuan, W., & Tong, X. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05891-7 · Cited by 5
Orgueira, A. M., Perez, M. S. G., D’Agostino, M., Cairns, D. A., Larocca, A., Palacios, J. J. L., Wester, R., Bertsch, U., Waage, A., Zamagni, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70228 · Cited by 6
“62,63”
Self-citationChoosing the optimal maintenance strategy in multiple myeloma
Puliafito, B. R., Cirstea, D. D., & Raje, N. S. (2025) · Hematology · doi:10.1182/hematology.2025000732 · Cited by 4
Xu, J., Shu, M., Chung, H., Cui, J., Liu, Y., Yan, W., Bai, Q., Dai, N., Li, L., Zhou, J., et al. (2025) · Cancers · doi:10.3390/cancers18010053 · Cited by 7
“…of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies has revolutionized the management of newly diagnosed multiple myeloma (NDMM), extending the survival of patients with NDMM significantly both in clinical trials and real-world practice [5–9].”
Self-citationBal, S., Ravi, G., Dhakal, B., Callander, N. S., Medvedova, E., Dholaria, B., Giri, S., Godby, K. N., Silbermann, R. W., Mikhail, F. M., et al. (2026) · Blood · doi:10.1182/blood.2025031952 · Cited by 5
Lee, H. C., Ramasamy, K., Macro, M., Davies, F. E., Abonour, R., van Rhee, F., Hungria, V. T. M., Puig, N., Ren, K., Šilar, J., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14214 · Cited by 4
Self-citationTheranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy
Bogdanovic, B., Hugonnet, F., & Montemagno, C. (2025) · Cancers · doi:10.3390/cancers17071247 · Cited by 8
“…been explored for both imaging and therapeutic applications. mAbs such as daratumumab and isatuximab have been radiolabeled with 89 Zr and evaluated in mouse models of MM. Specifically, 89 Zr-DFO-isatuximab enabled the visualization of disseminated MM as well as Burkitt’s lymphoma models [104].”
Freeman, C. L. L., Abraham-Miranda, J., Menges, M. A., Atkins, R. M., Noble, J. D., Liu, H. D., Corallo, S. A., Delgado, L. A. C., Ribickas, A. J., Savid-Frontera, C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.019 · Cited by 5
Storck, A., Beutel, G., Kochanek, M., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06400-3 · Cited by 4
“…in classic Hodgkin lymphoma [ 9 ], CD38-directed antibodies (e.g. daratumumab) and proteasome inhibitors (e.g. bortezomib) in multiple myeloma [10 ], and tyrosine kinase inhibitors (e.g. imatinib) in chronic myeloid leukemia and Philadelphia chromo-some-positive acute lymphoblastic leukemia…”
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma
Mo, C. C., Liu, Y., Hartley-Brown, M. A., Nadeem, O., Midha, S., & Richardson, P. G. G. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.003 · Cited by 4
Self-citationXiong, S., Zhou, J., & Chng, W. J. (2025) · Blood · doi:10.1182/blood.2025028403 · Cited by 4
Firestone, R., Simhal, A. K., McAvoy, D. P., Jurgens, E. M., Garcés, J., Nemirovsky, D., Derkach, A., Maclachlan, K. H., Hultcrantz, M. L., Mailankody, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0572 · Cited by 4
Venglár, O., Radova, E., Broskevičová, L., Hájek, R., & Jelínek, T. (2025) · Cytometry Part A · doi:10.1002/cyto.a.24962 · Cited by 6
Yan, W., Du, C., Lv, R., Zou, H., Zhang, S., Yu, T., Yan, Y., Zhang, Y., Peng, S., Wang, T., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01969 · Cited by 7
Self-citationZhang, F., Liu, S., Zhou, X., Wang, W., Jia, C., Wang, Q., Liu, Y., & Zhuang, J. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100615 · Cited by 4
Self-citationMohyuddin, G. R., Guadamuz, J. S., Ascha, M. S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013600 · Cited by 4
The 5T's of health disparities in multiple myeloma in Latin America
Martínez‐Cordero, H., Fuentes-Lacouture, M. C., Glasenapp, A. V., & Peña, C. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001088 · Cited by 4
Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma
Lai, E. E. N., Soon, Y. Y., Lee, A. R. Y. B., Wong, S. Y., Soekojo, C. Y., Ooi, M. G. M., Chng, W. J., & Mel, S. D. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100042 · Cited by 4
Tso, A. C. Y., Chng, W. J., Goh, Y. T., Ooi, M. G. M., Chen, Y., Nagarajan, C., Tan, D. C. L., Acharyya, S., & Ong, K. H. (2024) · Clinical Hematology International · doi:10.46989/001c.124362 · Cited by 9
Marcoux, C., Pasvolsky, O., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., Nieto, Y. L., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.10.011 · Cited by 4
What is the ideal approach—doublet, triplet, or quadruplet(s)?
Kumar, S. K. (2024) · Hematology · doi:10.1182/hematology.2024000581 · Cited by 7
Richardson, P. G. G. (2024) · Hemato · doi:10.3390/hemato5020012 · Cited by 6
Borst, N., Ihorst, G., Wenger, S., Räder, J., Wäsch, R., Engelhardt, M. M., & Rassner, M. P. (2024) · Cancers · doi:10.3390/cancers16234090 · Cited by 4
“Induction therapy in most studies consisted of triplets such as VCD, or bortezomib– lenalidomide–dexamethasone (VRd)/lenalidomide–adriamycin–dexamethasone (RAD), consistent with the DSMM XI and XIV studies [17] and in line with other centers now using D-VRd according to the PERSEUS study [11].”
Mian, H. S., Visram, A., Shih, S. C.-M., Trudel, S., Hay, A. E., LeBlanc, R., Sébag, M., Kaedbey, R., Stakiw, J., Sandhu, I., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.010 · Cited by 3
Varga, C., Robinson, M. M., Gupta, V. A., Hofmeister, C. C., Nooka, A. K., Kaufman, J. L., Dhodapkar, M. V., Lonial, S., Borden, S., Ferreri, C. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.003 · Cited by 6
Ranganathan, S., & Prasad, V. K. (2025) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2025.100588 · Cited by 4
Rüsing, L. Z., Schweighofer, J., Aschauer, J., Jeryczynski, G., Vospernik, L., Gisslinger, H., Bumberger, A. M., Cserna, J., Riedl, J., Agis, H., et al. (2025) · Cancers · doi:10.3390/cancers17142398 · Cited by 3
“Quadruplet therapies incorporating all these agents have been approved recently for first-line therapy [6].”
Qiao, S., Long, H., Song, Y. S., et al. (2025) · RSC Advances · doi:10.1039/d5ra04640h · Cited by 3
Self-citationFoster, L. H., Anderson, L. D., Chung, A., Chaulagain, C. P., Pettijohn, E. M., Cowan, A. J., Costello, C. L., Larson, S., Sborov, D. W., Shain, K. H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01355-0 · Cited by 4
Self-citationMultiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations
Pires, A. M., Barreto, J. P., Caetano, J., Soares, M. J., Geraldes, C., Fernandes, B., Coucelo, M., Chacim, S. P., Coelho, H. G. B., Correia, C., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197115 · Cited by 6
Li, J., Feng, H., Liu, K., Huang, H., Ji, X., Zhang, T., Cheng, X., & Zhao, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-18637-z · Cited by 5
“For example, the Bortezomib was the first approved ubiquitination inhibitor for the treatment of multiple myeloma 27, which inhibited the proteasome, thereby blocking the degradation of ubiquitinated proteins and ultimately induced tumor cell death.. Pitinib (MLN4924) impeded the functions of…”
Moreau, P., Hulin, C., Talbot, A., Demarquette, H., Caillot, L., Chalopin, T., Bobin, A., Manier, S., Leleu, X. P., Karlin, L., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01387-6 · Cited by 4
“Following CASSIOPEIA, induction therapy with a quadruplet regimen became SoC in 2020, an approach further supported by fi ndings from the GRIFFIN [33], PERSEUS [34], and GMMG-HD7 trials [35].”
Self-citationEndless possibilities and how to exploit them? What is the optimal treatment sequence?
Chakraborty, R., Bhutani, D., & Lentzsch, S. (2025) · Hematology · doi:10.1182/hematology.2025000760 · Cited by 3
Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis
Banerjee, R. K., King, T., Faiman, B., Harding, S., Rosenberg, A. S., Sanchorawala, V., Mikhael, J. R., & Cowan, A. J. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01713 · Cited by 4
Xin, X., Fan, C., Sheng, R., Li, X. C., Zhu, X., Huang, Y., Seraji, H. R., Urazbaeva, D., Atamuratova, Z., & Ubaydullaevna, A. D. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02050-5 · Cited by 4
“The addition of daratu - mumab (D-VRd) in the GRIFFIN and PERSEUS trials has further enhanced MRD negativity rates and PFS, establishing quadruplet therapy as the new benchmark for first-line treatment [188, 191 ].”
Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence
Davidson, J., Kumar, A. D., Patel, A. R., Chen, I. Y., Butte, A. J., & Zack, T. I. (2026) · Cancers · doi:10.3390/cancers18040669 · Cited by 6
MRD in multiple myeloma: the clinical perspective
di Toritto, T. C., & Rago, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1740112 · Cited by 5
The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma
Barachini, S., Cassano, R. C., Ronca, F., Petrini, I., Galimberti, S., & Buda, G. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70168 · Cited by 3
How I treat plasma cell leukemia
Hadidi, S. A., van Rhee, F., & Anderson, L. D. (2026) · Blood · doi:10.1182/blood.2025032145 · Cited by 4
Hughes, C., Shah, G. L., & Paul, B. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1373548 · Cited by 4
Gu, X., Tang, W., Zhang, L., Zheng, Y., Pan, L., & Niu, T. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01445-6 · Cited by 3
“Ten open-label studies aroused some concerns in terms of deviations from the intended interventions [24, 25, 28–30, 33–35, 38, 39].”
BackgroundMethodCosta, B. A., Costa, T. A., Chagas, G. C. L., Mouhieddine, T. H., Richter, J. R., Usmani, S. Z., Mailankody, S., Rajeeve, S., & Hashmi, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.09.008 · Cited by 3
Peery, M. R., Hill, H., Sharps, A., Zaver, A., & Moore, D. C. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241282115 · Cited by 3
Costa, L. J., Gay, F., Landgren, O., Mateos, M., Moreau, P., Touzeau, C., Ertel, F., McFadden, I., Najdi, R., & Weisel, K. C. (2025) · Annals of Hematology · doi:10.1007/s00277-024-06143-7 · Cited by 3
“For example, in the PERSEUS trial, the MRD– rate (10 –5 ) post-consolidation was 57.5% with Dara-VRd, translating to an estimated 4-year PFS rate of 84% [27].”
InfluentialSelf-citationVenglár, O., Radova, E., Žihala, D., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27590 · Cited by 3
Macrofocal multiple myeloma in the era of novel agents in China
Dou, X., Liu, R., Yang, L., Peng, N., Wen, L., Deng, D.-X., Cao, L., Li, Q., Wang, L., Wang, F., et al. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251314696 · Cited by 3
Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma
Carlson, S. G., Lin, T. L., & Larson, S. M. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2461987 · Cited by 5
Richter, J. R., Nooka, A. K., Rodríguez‐Otero, P., Schjesvold, F. H., Katodritou, E., Combe, E., Scott, M., Cooper, L., Sly, I., Ballew, N., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27661 · Cited by 3
“Use of lenalidomide in the first and second line, and rising daratumumab use are likely leading to a high number of patients who are triple class-refractory (i.e., to a PI, an immunomodulatory drug, and an anti-CD28 monoclonal antibody) [16, 54, 55].”
Self-citationBenda, M. A., Reimann, P., Bletzacher, E., Muendlein, A., Bernhard, B. S., Hartmann, B. L., Huynh, M., Gasser, K., Zojer, N., Lang, T., et al. (2025) · Cancers · doi:10.3390/cancers17081261 · Cited by 3
“The review further highlights the efficacy of isatuximab and discusses the lack of data on daratumumab in this setting [6].”
InfluentialTalbot, A., Hulin, C., Perrot, A., Macro, M., Merzoug, K. B., Mohty, M., Bobin, A., Karlin, L., Manier, S., Vincent, L., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.015 · Cited by 4
Self-citationCurrent and Future Directions of Immunotherapies in Multiple Myeloma
Biltibo, E. A., Surapaneni, M., Hadidi, S. A., Suvannasankha, A., & Jayani, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473316 · Cited by 5
Daratumumab for High-Risk Smoldering Multiple Myeloma
Dimopoulos, M. A., Voorhees, P. M., & Rajkumar, S. V. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2507790 · Cited by 3
Self-citationUzun, D., Paul, J. M., Jensen, A. M., Tamaresis, J. S., Domingo, W., Arai, S., Ventura, F. A., Rocha, J., Bennett, L., Jones, A., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.08.014 · Cited by 8
Kumar, L., Chethan, R., Malik, P. S., Pramanik, R., Sahoo, R. K., Biswas, A., Sharma, O. D., Gupta, R., Sharma, A., & Mallick, S. (2025) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2025.100680 · Cited by 3
Venkatesh, P., Ravi, G., Dhakal, B., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70359 · Cited by 3
Updates to the Management of Multiple Myeloma
Callander, N. S., & Kumar, S. K. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.5004 · Cited by 4
Metadata
- Authors
- Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
- Affiliations
- University Medical Center Groningen (NL)
- The University of Sydney (AU)
- From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
- Oslo University Hospital (NO)
- Jagiellonian University (PL)
- ORCID
- Sonneveld, Pieter
- Dimopoulos, Meletios A.
- Boccadoro, Mario
- Quach, Hang
- Ho, P. Joy
- Hulin, Cyrille
- Antonioli, Elisabetta
- Leleu, Xavier
- Mangiacavalli, Silvia
- Perrot, Aurore
- Belotti, Angelo
- Broijl, Annemiek
- Gay, Francesca
- Mina, Roberto
- Katodritou, Eirini
- Schjesvold, Fredrik
- Rosiñol, Laura
- Delforge, Michel
- Roeloffzen, Wilfried
- Silzle, Tobias
- Vangsted, Annette
- Einsele, Hermann
- Spencer, Andrew
- Jurczyszyn, Artur
- Ahmadi, Tahamtan
- Liu, Yanfang
- Wang, Jianping
- Sitthi-Amorn, Anna
- Bladé, Joan
- Moreau, Philippe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-25
- Volume
- 390
- Issue
- 4
- Pages
- 301-313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389606680
- Cited by
- 599
- References
- 23
- Citations by year
- 2026: 198 · 2025: 252 · 2024: 145
- FWCI
- 123.04
- Type
- journal article
- Language
- en
- Open access
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
- MeSH terms
- Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


